Key result
Catheter ablation proves safe and effective over AADs as first-line therapy for paroxysmal AF.
Why the study?
Does catheter ablation as first-line treatment improve outcomes compared to antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation?
Does catheter ablation as first-line treatment improve outcomes compared to antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation?
Catheter ablation, particularly cryoballoon ablation, is supported by ESC guidelines as an effective and safe first-line treatment for paroxysmal atrial fibrillation compared to antiarrhythmic drugs.
Supports first-line cryoballoon ablation in paroxysmal AF; leaves open need for updated long-term outcome trials.
<ns3:p>Current ESC guidelines present several indications for catheter ablation as a first-line treatment of paroxysmal atrial fibrillation. Those indications reflect high effectiveness and safety of catheter ablation also in comparison to antiarrhythmic drug therapy. Cryoballoon ablation has a firm position as a first-line treatment of paroxysmal atrial fibrillation based on multicenter randomized controlled trials. To achieve similar outcomes, one must remember basic rules on how to perform cryoballoon ablation.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Michał M. Farkowski (2022) conducted a review in Paroxysmal atrial fibrillation. Catheter ablation (cryoballoon ablation) vs. Antiarrhythmic drug therapy was evaluated. Catheter ablation, particularly cryoballoon ablation, is an effective and safe first-line treatment for paroxysmal atrial fibrillation compared to antiarrhythmic drug therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: